Laurus Labs

₹589 7.5 | 1.3%

WEBSITE BSE:540222 NSE : LAURUSLABS 18 Mar, 16:01

Market Cap ₹31762 Cr.

Stock P/E 188.8

P/B 7.5

Current Price ₹589

Book Value ₹ 78.3

Face Value 2

52W High ₹646.3

Dividend Yield 0.14%

52W Low ₹ 372.2

Edit Ratio

Laurus Labs Research see more...

Overview Inc. Year: 2005Industry: Pharmaceuticals & Drugs

Laurus Labs Ltd is an India-based producer of active pharmaceutical ingredients (APIs) for anti-etrovirals (ARVs), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology. The Company develops and manufactures oral stable formulations, gives contract research and manufacturing services (CRAMS) and contract development and manufacturing company (CDMO) to the global pharmaceutical companies. The Company also produces special substances for nutraceuticals, dietary supplements, and cosmeceuticals. Its business gadgets includes Generics APIs, Generics Finished Dosage Forms (FDFs) and Synthesis/Ingredients. The Generics APIs enterprise accommodates the development, manufacture and sale of APIs and advanced intermediates inside the ARV, Hepatitis C, oncology, cardiovascular, anti-diabetic, anti-asthmatic, gastroenterology and ophthalmic therapeutic regions. The Generics FDFs is engaged in growing and manufacturing oral stable formulations.

Laurus Labs Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Laurus Labs Quarterly Results

#(Fig in Cr.)	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Net Sales	1576	1545	1381	1182	1224	1195	1440	1195	1224	1415
Other Income	1	1	2	4	2	2	19	3	5	9
Total Income	1577	1546	1383	1185	1226	1197	1458	1197	1228	1424
Total Expenditure	1127	1141	1095	1015	1037	1014	1198	1024	1045	1130
Operating Profit	450	405	287	170	190	184	260	174	183	295
Interest	40	43	53	39	42	51	51	49	53	58
Depreciation	82	84	87	91	93	98	102	106	108	106
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	328	278	147	41	54	35	107	18	23	131
Provision for Tax	94	75	40	12	15	9	32	6	5	40
Profit After Tax	234	203	107	28	39	25	75	12	18	91
Adjustments	-1	-0	-4	-4	-2	-2	0	0	2	2
Profit After Adjustments	233	203	103	25	37	23	76	13	20	92
Adjusted Earnings Per Share	4.3	3.8	1.9	0.5	0.7	0.4	1.4	0.2	0.4	1.7

Laurus Labs Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	1160	1327	1778	1905	2056	2292	2832	4814	4936	6041	5041	5274
Other Income	9	34	4	33	29	16	6	24	15	6	26	36
Total Income	1169	1361	1782	1938	2085	2308	2838	4837	4951	6047	5067	5307
Total Expenditure	956	1131	1415	1497	1643	1936	2267	3263	3513	4448	4263	4397
Operating Profit	212	229	367	441	443	372	570	1574	1438	1598	804	912
Interest	59	101	111	100	80	88	90	68	102	165	183	211
Depreciation	33	62	86	106	125	164	187	205	251	324	385	422
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	121	67	169	235	237	120	294	1301	1084	1109	236	279
Provision for Tax	24	-2	35	44	70	26	38	317	251	312	68	83
Profit After Tax	97	68	134	191	168	94	255	984	832	797	168	196
Adjustments	0	0	-0	-1	0	0	0	-0	-5	-12	-11	4
Profit After Adjustments	97	68	134	190	168	94	255	984	828	785	158	201
Adjusted Earnings Per Share	3.2	2.2	4.2	3.6	3.2	1.8	4.8	18.3	15.4	14.6	2.9	3.7

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-17%	2%	17%	16%
Operating Profit CAGR	-50%	-20%	17%	14%
PAT CAGR	-79%	-45%	12%	6%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	48%	-0%	53%	NA%
ROE Average	4%	18%	23%	20%
ROCE Average	7%	19%	22%	18%

Laurus Labs Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	358	722	857	1330	1483	1558	1770	2598	3351	4038	4111
Minority's Interest	0	0	0	0	0	0	0	3	8	11	5
Borrowings	188	304	460	125	142	259	165	429	596	761	798
Other Non-Current Liabilities	16	60	-32	8	33	37	49	264	332	418	361
Total Current Liabilities	711	802	884	1121	1307	1424	1692	2457	2681	2432	3112
Total Liabilities	1273	1888	2169	2584	2964	3278	3676	5751	6968	7660	8387
Fixed Assets	499	801	1021	1230	1481	1629	1726	2171	2652	3409	3890
Other Non-Current Assets	197	223	145	214	235	186	138	505	971	790	662
Total Current Assets	575	862	1003	1140	1248	1463	1812	3075	3345	3462	3835
Total Assets	1273	1888	2169	2584	2964	3278	3676	5751	6968	7660	8387

Laurus Labs Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	3	15	40	13	2	3	3	2	48	75	46
Cash Flow from Operating Activities	121	-65	182	332	342	298	347	733	911	994	666
Cash Flow from Investing Activities	-312	-397	-312	-289	-384	-253	-221	-941	-914	-996	-822
Cash Flow from Financing Activities	203	486	103	-54	42	-45	-128	255	30	-27	250
Net Cash Inflow / Outflow	12	24	-27	-10	1	0	-1	47	27	-29	93
Closing Cash & Cash Equivalent	15	40	13	2	3	3	2	48	75	46	139

Laurus Labs Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	3.16	2.2	4.24	3.56	3.16	1.76	4.78	18.33	15.4	14.56	2.93
CEPS(Rs)	4.23	4.18	6.99	5.62	5.53	4.85	8.28	22.16	20.17	20.81	10.26
DPS(Rs)	0	0	0.4	0.3	0.3	0.3	0.5	2	2	2	0.8
Book NAV/Share(Rs)	9.46	20.98	24.96	25.05	27.86	29.18	33.02	48.32	62.19	74.73	75.88
Core EBITDA Margin(%)	17.47	14.58	20	21.1	19.98	15.53	19.94	32.22	28.82	26.36	15.42
EBIT Margin(%)	15.4	12.53	15.47	17.35	15.32	9.07	13.53	28.45	24.03	21.09	8.32
Pre Tax Margin(%)	10.37	4.98	9.33	12.18	11.47	5.22	10.37	27.03	21.96	18.36	4.69
PAT Margin (%)	8.34	5.09	7.41	9.91	8.1	4.09	9.01	20.44	16.87	13.19	3.34
Cash Profit Margin (%)	11.16	9.69	12.18	15.39	14.16	11.26	15.63	24.7	21.96	18.55	10.97
ROA(%)	7.64	4.31	6.61	8.05	6.04	3	7.34	20.87	13.09	10.89	2.1
ROE(%)	33.42	14.47	18.65	18.12	11.97	6.19	15.39	45.15	28.05	21.63	4.15
ROCE(%)	19.96	13.74	16.35	16.52	13.68	8.22	14.14	39.82	25.97	22.97	6.64
Receivable days	61.02	65.47	73.56	95.66	100.4	101.97	96.76	79.52	98.37	88.66	117.42
Inventory Days	102.73	109.61	97	94.12	96.48	100.87	102.29	94.05	123.34	104.09	127.81
Payable days	115.25	101.84	87.3	94.21	99.44	119.3	145.69	155.37	175.76	106.1	135.42
PER(x)	0	0	0	28.91	31.83	45.38	13.51	19.75	38.31	20.12	133.9
Price/Book(x)	0	0	0	4.11	3.61	2.74	1.95	7.49	9.49	3.92	5.16
Dividend Yield(%)	0	0	0	0.29	0.3	0.38	0.77	0.55	0.34	0.68	0.2
EV/Net Sales(x)	0.52	0.64	0.61	3.3	3.07	2.31	1.59	4.33	6.76	2.93	4.66
EV/Core EBITDA(x)	2.81	3.68	2.95	14.25	14.26	14.21	7.9	13.23	23.2	11.08	29.21
Net Sales Growth(%)	0	14.39	34	7.15	7.96	11.47	23.55	69.99	2.54	22.39	-16.55
EBIT Growth(%)	0	-6.62	67.08	19.61	-5.38	-34.42	84.28	257.33	-13.37	7.41	-67.09
PAT Growth(%)	0	-29.93	96.91	42.64	-12.4	-44.06	172.25	285.4	-15.39	-4.3	-78.89
EPS Growth(%)	0	-30.27	92.45	-15.95	-11.31	-44.27	171.04	283.84	-15.98	-5.42	-79.91
Debt/Equity(x)	1.54	1.14	1.2	0.64	0.66	0.67	0.6	0.56	0.52	0.49	0.61
Current Ratio(x)	0.81	1.07	1.13	1.02	0.95	1.03	1.07	1.25	1.25	1.42	1.23
Quick Ratio(x)	0.35	0.48	0.58	0.56	0.51	0.55	0.54	0.61	0.59	0.73	0.64
Interest Cover(x)	3.06	1.66	2.52	3.35	3.98	2.36	4.28	20.09	11.59	7.71	2.29
Total Debt/Mcap(x)	0	0	0	0.15	0.18	0.24	0.31	0.07	0.05	0.12	0.12

Laurus Labs Shareholding Pattern

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	27.27	27.2	27.2	27.2	27.2	27.19	27.19	27.18	27.18	27.62
FII	22.65	21.89	22.4	22.52	24.03	25.39	25.97	25.67	26.08	25.56
DII	9.33	9.53	9.75	10.35	11.01	11.13	11.77	13.56	13.05	12.74
Public	40.75	41.39	40.64	39.93	37.76	36.29	35.07	33.59	33.69	34.08
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	14.65	14.65	14.65	14.65	14.65	14.65	14.65	14.65	14.65	14.9
FII	12.17	11.79	12.07	12.13	12.94	13.68	14	13.84	14.06	13.78
DII	5.02	5.13	5.25	5.57	5.93	6	6.34	7.31	7.03	6.87
Public	21.9	22.29	21.89	21.51	20.34	19.56	18.9	18.11	18.17	18.38
Others	0	0	0	0	0	0	0	0	0	0
Total	53.74	53.87	53.87	53.87	53.87	53.9	53.9	53.92	53.92	53.93

Pros

Cons

Promoter holding is low: 27.62%.
Debtor days have increased from 106.1 to 135.42days.
Stock is trading at 7.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Laurus Labs News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Laurus Labs

Add Watchlist

Laurus Labs Research see more...

Overview Inc. Year: 2005Industry: Pharmaceuticals & Drugs

Laurus Labs Share Price

Alert Data

Quarterly Price

Peer Comparison

Laurus Labs Quarterly Results

Laurus Labs Profit & Loss

Growth Rates

Laurus Labs Balance Sheet

Laurus Labs Cash Flow

Laurus Labs Ratios

Laurus Labs Shareholding Pattern

Laurus Labs News

IPO

Sharescart: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!

Enter Your Complaint